INTRODUCTION
============

Anal fistula is the most common perianal lesion of Crohn's disease (CD). Its incidence has been reported approximately 35%[@B12], and 5% of patients first manifest anal fistula[@B3]. Clinical characteristics are keys to improve identification and treatment, so that large sample analysis is of great value.

The objective of this study was to explore the clinical features of anal fistula in CD to better indicate the appropriate treatment

METHOD
======

This study was approved by the Ethics Committee of the institution under the number 2015NL-126-03

Research subjects and observation indexes
-----------------------------------------

Cases of 139 perianal fistulising CD patients, who were first admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine from January 2010 to January 2017, were registered to collect their gender, age, CD course, anal fistula course, body mass index (BMI), Montreal classification, anal fistula type, external opening number, concomitant perianal lesions, clinical symptoms, abdominal surgery history, perianal surgery history, medication history, CD activity index (CDAI), perianal disease activity index (PDAI) and laboratory analyses, as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), leukocyte (WBC), platelet (PLT), hemoglobin (HB), albumin (Alb).

Criteria of clinical assessment and classification
--------------------------------------------------

The nutritional status was evaluated by BMI. The Montreal Phenotypic Classification[@B14], proposed by the 2005 World Gastroenterology Working Group, was used to classify CD. It´s activity index was evaluated by Best's CDAI^2^ calculation. The activity of anal fistula in CD was evaluated by PDAI[@B7]. Anal fistula was divided into simple and complex types[@B1] according to the 2003 American Gastroenterological Association Statement on Perianal CD.

RESULTS
=======

[Table 1](#t1){ref-type="table"} shows basic statistics of the 139 cases, including gender, CD course, anal fistula course, surgery history and medication history. The proportion of male to female is about 3.3:1. The CD courses range from 0 month to 12 years, with an average of 28±38 months. Anal fistula courses range from 0 month to 10 years, with an average of 25±29 months. Twenty-seven patients had abdominal surgery history, accounting for 19.4%. Ninety had perianal surgery history, accounting for 64.7%. Perianal abscess surgeries were related in 40.3% of patients, holding the largest proportion, followed by anal fistula surgery in 27.3%. Medication history accounted in 74.1% of patients and most of them (44.6%) used 5-aminosalicylic (5-ASA).

TABLE 1The basic clinical featuresItem n (%)Gendermale107 (77.0)female32 (23.0)CD course\<1year79 (56.8)1\~10year54 (38.8)\>10 year6 (4.3)Anal fistula course\<1 year74 (53.2)1\~10 year60 (44.6)\>10 year5 (3.6)Relationship between the two coursesAnal fistula appears first Simultaneously CD diagnosed first66 (47.5%) 27 (19.4%) 46 (33.1%)Number of previous abdominal surgeries123 (16.5)\>14 (2.9)Perianal surgeries historyAnal fistula surgery38 (27.3)Perianal abscess surgery56 (40.3)Hemorrhoids surgery6 (4.3)Anal fissure surgery2 (1.4)Else♦1 (0.7)Number of previous perianal surgeries158 (41.7)\>132 (23.0)Medication historyYes 5-ASA103 (74.1) 62 (44.6)SASP15 (10.8)Immunosuppressor24 (17.3)Corticosteroid31 (22.3)Biologics22 (15.8)Antibiotic16 (11.5)Enteral nutrition28 (20.1)Else\*23 (16.5)[^2]

The Montreal phenotype are shown in [Table 2](#t2){ref-type="table"}. The age ranged from 13 to 59 years (28.2±8.48), and 85.6% of them were of the type A2. Type L3 had the highest proportion up to 49.6%. The types B1 and B2 were common, accounting for 51.8% and 48.2% respectively. In this data, the anorectal stenosis was included in type B2 and the penetration of anal fistula was excluded from type B3.

TABLE 2The Montreal phenotypesItem n (%)Age (A)A1 (≤16)6 (4.3)A2 (17\~40)119 (85.6)A3 (\>40)14 (10.0)Location (L)L1 (ileum)33 (23.7)L2 (colon)37 (26.6)L3 (ileocolon)69 (49.6)L4 (upper gastrointestinal)5 (3.6)Behavior (B)B1 (nostricturing, no penetrating)72 (51.8)B2 (stricturing)67 (48.2)B3 (penetrating)10 (8.6)

Anal fistula type, external opening number, and other concomitant perianal diseases are shown in [Table 3](#t3){ref-type="table"}. The incidence of complex anal fistula is relatively higher, up to 90.6%. The incidences of anorectal stenosis and verrucous skin were 33.1% and 30.9%, higher than those of other concomitant anal diseases.

TABLE 3Anal fistula type, external opening number, and other concomitant perianal diseasesItem n (%)Anal fistula typeSimple anal fistula13 (9.4)Complex anal fistula126 (90.6)External opening number148 (34.5)244 (31.7)≥347 (33.8)Concomitant perianal diseasesAnorectal stenosis46 (33.1)Fissure6 (4.3)Abscess33 (23.7)Rectovaginal fistula7 (5.0)Verrucous skin43 (30.9)

The clinical symptoms are shown in [Table 4](#t4){ref-type="table"}. Diarrhea was the most common symptom, accounting for 46% of the 139 patients. Meanwhile, 29.5% merely have perianal symptoms.

TABLE 4The clinical symptomsItemn (%)Abdominal pain30 (23.0)Diarrhea64 (46.0)Fever27 (19.4)Loss of weight37 (26.6)Anaemia21 (15.1)Hematochezia23 (16.5)Perianal symptoms only41 (29.5)

The BMI, CDAI and PDAI values are shown in [Table 5](#t5){ref-type="table"}. Abnormal BMI values were found in 44.6% and 35.3% had CDAI ratings classified as "Very Well", i.e. in remission, while 38.1% have ratings of "Fair to Good". According to their PDAI scores, 94.2% of patients were in active stage of perianal diseases.

TABLE 5The BMI, CDAI and PDAI valuesItem n (%)BMI\<18.5 kg/m262 (44.6)≥18.5 kg/m277 (55.4)CDAIVery well (\<150 points)49 (35.3)Fair to good (150\~220 points)53 (38.1)Poor (221\>450 points)37 (26.6)Very poor (\>450 points)0 (0)PDAIRemission stage (≤4 points)8 (5.6)Active stage (\>4 points)131 (94.2)

The laboratory analyses are shown in [Table 6](#t6){ref-type="table"}. CRP increasing was present in 38.1% of patients; 53.2% for ESR accelerating, 38.8% for HB decreasing, 36.0% for PLT increasing, 23.7% for Alb decreasing.

TABLE 6The common laboratory indexesItem n (%)CRP (mg/l)≥853 (38.1)\<886 (61.9)ESR^a^ (mm/h)Above normal74 (53.2)Normal65 (46.8)HB^b^ (g/l)Below normal54 (38.8)Normal85 (61.2)PLT (109/l)\<1001 (0.7)≥30050 (36.0)100\~30088 (63.3)WBC (109/l)\<1013 (9.4)4\~10115 (82.7)\>411 (7.9)Alb (g/L)35\~50103 (74.1)\<35 \>5033 (23.7) 3 (2.2)[^3]

DISCUSSION
==========

Studies in developed countries suggest that the incidence of CD is bimodal distribution, reaching the first peak at the age of 20-39 and second and lower peak at the age of 60-79[@B10]. But according to epidemiological studies in China, the second peak is not significant[@B9]. In our study, the mean age of patients was 28.2 years, and 85.6% were type A2, which is close to the study in Southern China by Song XM et al.[@B15], reporting it in 70.7% among 205 patients. In western countries, the distribution of lesion locations is even, but in China the type L3 is most common, with a ratio of 61-71%[@B18] ^,^ [@B19]. In our study, type L3 accounted for 49.6% of cases, slightly lower than other China reports, but still significantly higher than type L1 and type L2. As for disease behaviors, Ng et al[@B11]reported that the ratios of B1, B2 and B3 of CD patients in Hong Kong were 65.2%, 25.1% and 16.1%, respectively. Zhao Jet al^19^ reported that the B1, B2 and B3 ratios were 44%, 29%, and 24%, respectively. In our study, the ratio of B1 was 51.8%, which is consistent with other China studies, but the ratio of B2 of 48.2% was significantly higher than other China studies. One of the possible reasons is that 33.1% of perianal fistulising CD patients with anorectal stenosis are classified as L2.

In most western developed countries, the number of female CD patients is more than male[@B9], and the ratio of male to female is 1:1.46. On the contrary, in Asia the ratio is near 1:1, and, in many cases, male are far more[@B8] ^,^ [@B11] ^,^ [@B15]. In our study, the male and female ratio was near 3.3:1, which is consistent with other Asian reports. Perianal surgery history was present in 64.7% mostly for perianal abscess and anal fistula, and 23% had more than one surgery. Medication use of 5-aminosalicylic derivatives were related by 44.6% of patients, while the 2016 ECCO Consensus^5,6^ denied the clinical benefits of 5-aminosalicylic derivatives for CD patients, and recommended IFX, immunosuppressive drugs and antibiotics for perianal fistulising CD.

The prevalence of anal fistula varies according to disease location. Perianal fistulae were noted in 12% with isolated ileal disease, 15% with ileocolonic disease, 41% with colonic disease and rectal sparing, and 92 % with colonic disease involving the rectum[@B5]. In our study, anal fistulas are usually accompanied by anorecal stenosis and verrucous skin, suggesting that proctitis exists. Due to the progress in itself CD can lead to internal and external sphincter and perineal damage, and proctitis leads to reduced rectal compliance. Even moderate level of sphincter function decline may eventually lead to incontinence because of obstruction of water absorption in the colon and decreased rectal capacity and compliance[@B16]. Therefore, patients of perianal fistulising CD with proctitis should accept abscess drainage or non-cutting seton, rather than definitive surgery to promote fistula closure[@B4].

The ECCO Consensus^5^ suggested that perianal diseases may occur before intestinal symptoms or simultaneously to it. Schwartz D A et al^13^ found that only 5% of CD patients first manifest anal fistula without any intestinal inflammation. In this study, 47.5% of patients had anal fistula before the occurrence of intestinal inflammation, and 29.5% presented perianal lesions only. These percentages, which are much higher than previous report[@B13], suggest that isolated anal fistula without intestinal inflammation could not rule out the possibility of CD. "Very well" or "Fair to Good" stages of CDAI were present in 73.4%, but 94.2% of them were in active stage of PDAI, i.e. their intestinal inflammations were controlled better than their perianal diseases. The possible reason is that most of our patients had received basic treatment to control intestinal inflammation before they came to our hospital.

Malnutrition is one of the most common symptoms of IBD, and its incidence is up to 85%. Protein energy malnutrition is the most common type, characterized by emaciation and weight loss. Its incidence is associated with reduced intake of food in fear of bowel symptoms triggered by eating, and loss of nutrients and nutritional in taking disorders caused by intestinal lesions. Some of our patients showed low BMI, low Alb, low HB and weight loss. These abnormalities remind us to assess and correct the nutritional status of patients. Endoscopic mucosal healing is the goal of CD treatment; previous study^17^ have shown that CD simplified endoscopic score (SES-CD) is correlated with the commonly used clinical indexes of inflammation, e.g. CRP, ESR and PLT, but the accuracy is poor. The method of calprotectin detection has higher accuracy to detect endoscopic activity, compared to other clinical and laboratory indexes. In this study, patients with high ESR, CRP and PLT account for 53.2%, 38.1% and 36%, respectively, indicated activity of intestinal inflammation. Our center has not yet carried out faecal calpain detection, so, there was no relevant laboratory data.

CONCLUSION
==========

We suggest that patients with anal fistula associated to these clinical features should alert the medical team to the possibility of CD, which should be further investigated through endoscopy and imaging examination of alimentary tract to avoid the damage of anal function by routine anal fistula surgery.
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